Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Summary

The purpose of this study was to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab. This study also evaluated the clinical response and other measures of anticancer activity of ASP0739 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.

Timeline

Start

2021-12-23

Primary completion

2023-06-01

Completion

2023-06-01

Outcome

Outcome not reported

Stopped: “The comprehensive assessment of other studies indicated the lack of significant monotherapy activity, therefore, team decided to terminate the study.”

Drugs

Indications